Notch Signaling Pathway in Neurodegeneration

Migration, Crosslink

📖

Notch Signaling Pathway in Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:59 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-notch-signaling-neurodeg

📖 Wiki Page

mechanism2006 wordssynced 2026-04-02

Notch Signaling Pathway in Neurodegeneration

Introduction

The Notch signaling pathway represents one of the most evolutionarily conserved intercellular communication mechanisms in multicellular organisms. Originally identified in Drosophila melanogaster where Notch mutations caused notches in fly wings, this pathway now recognized as a critical regulator of cell fate, differentiation, proliferation, and apoptosis throughout the nervous system [1](https://pubmed.ncbi.nlm.nih.gov/10625483/). In the context of neurodegeneration, Notch signaling plays complex and often contradictory roles, contributing to both neuroprotective processes and pathological mechanisms in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions [2](https://pubmed.ncbi.nlm.nih.gov/18599442/). [@iso2003]

Notch receptors are transmembrane proteins that mediate direct cell-cell communication through ligand binding. The mammalian genome encodes four Notch receptors (Notch1-4) and five ligands (Delta-like 1, 3, 4 and Jagged 1, 2). Upon ligand binding, proteolytic cleavage releases the Notch intracellular domain (NICD), which translocates to the nucleus and regulates gene expression through interaction with CSL (CBF1/Su(H)/Lag-1) transcription factors and co-activators of the Mastermind family [3](https://pubmed.ncbi.nlm.nih.gov/10804160/). [@andersson2014]

Notch Signaling Mechanism

Receptor Structure and Activation

Notch receptors are type I transmembrane proteins composed of multiple domains: [@gazdar2000]

...

Notch Signaling Pathway in Neurodegeneration

Introduction

The Notch signaling pathway represents one of the most evolutionarily conserved intercellular communication mechanisms in multicellular organisms. Originally identified in Drosophila melanogaster where Notch mutations caused notches in fly wings, this pathway now recognized as a critical regulator of cell fate, differentiation, proliferation, and apoptosis throughout the nervous system [1](https://pubmed.ncbi.nlm.nih.gov/10625483/). In the context of neurodegeneration, Notch signaling plays complex and often contradictory roles, contributing to both neuroprotective processes and pathological mechanisms in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions [2](https://pubmed.ncbi.nlm.nih.gov/18599442/). [@iso2003]

Notch receptors are transmembrane proteins that mediate direct cell-cell communication through ligand binding. The mammalian genome encodes four Notch receptors (Notch1-4) and five ligands (Delta-like 1, 3, 4 and Jagged 1, 2). Upon ligand binding, proteolytic cleavage releases the Notch intracellular domain (NICD), which translocates to the nucleus and regulates gene expression through interaction with CSL (CBF1/Su(H)/Lag-1) transcription factors and co-activators of the Mastermind family [3](https://pubmed.ncbi.nlm.nih.gov/10804160/). [@andersson2014]

Notch Signaling Mechanism

Receptor Structure and Activation

Notch receptors are type I transmembrane proteins composed of multiple domains: [@gazdar2000]

Extracellular domain (NECD): [@berezovska2001]

Contains epidermal growth factor-like (EGF) repeats
Lin12-Notch repeats (LNR) prevent activation in the absence of ligand
Multiple ligand-binding sites [4](https://pubmed.ncbi.nlm.nih.gov/10625483/)

Transmembrane domain: [@wesenbeek2004]

Spans the membrane once
Contains the S2 cleavage site
Site of regulated intramembrane proteolysis (RIP) [5](https://pubmed.ncbi.nlm.nih.gov/10625483/)

Intracellular domain (NICD): [@selkoe2003]

Contains RAM domain for CSL binding
Ankyrin repeats for protein-protein interactions
Transcriptional activation domain (TAD) [6](https://pubmed.ncbi.nlm.nih.gov/10804160/)

Proteolytic Processing

Notch activation requires two sequential proteolytic cleavages: [@lathia2008a]

S1 cleavage (constitutive): [@wang2006]

Furin-like convertase in the trans-Golgi network
Generates heterodimeric receptor
Required for receptor maturation [7](https://pubmed.ncbi.nlm.nih.gov/10625483/)

S2 cleavage (regulated): [@kageyama2005]

Induced by ligand binding
A disintegrin and metalloproteinase (ADAM) family proteases
Releases extracellular fragment [8](https://pubmed.ncbi.nlm.nih.gov/10625483/)

S3 cleavage (regulated): [@aguirre2010]

γ-secretase complex performs this cleavage
Releases NICD to cytoplasm
Enables nuclear translocation [9](https://pubmed.ncbi.nlm.nih.gov/10625483/)

Canonical Notch Signaling

Once in the nucleus, NICD regulates transcription: [@prakash2006]

CSL-dependent transcription: [@stott2011]

NICD displaces transcriptional repressors
Recruits co-activators (MAML, p300)
Activates target gene expression [10](https://pubmed.ncbi.nlm.nih.gov/10804160/)

Key target genes: [@matsell2013]

Hes (Hairy and Enhancer of Split) family
Hey (Hairy/Enhancer-of-split related with YRPW motif) family
Cell cycle regulators
Apoptosis-related genes [11](https://pubmed.ncbi.nlm.nih.gov/18599442/)

Non-Canonical Notch Signaling

Notch can signal independently of CSL: [@grandbarbe2007]

Non-nuclear signaling: [@weidenfeld2012]

NICD can interact with cytoplasmic proteins
Modulates PI3K/Akt pathway
Affects mitochondrial function [12](https://pubmed.ncbi.nlm.nih.gov/18599442/)

Ligand-independent activation: [@ramos2010]

Mutations can cause constitutive activation
Alternative splicing generates truncated forms
Cross-talk with other pathways [13](https://pubmed.ncbi.nlm.nih.gov/18599442/)

Notch in Alzheimer's Disease

Amyloid-β and Notch

Alzheimer's disease involves complex interactions between Notch signaling and amyloid pathology: [@stott2013]

Notch processing alterations: [@lino2012]

Aβ can promote Notch cleavage
γ-secretase inhibitors reduce Aβ production
Shared cleavage machinery creates therapeutic challenges [14](https://pubmed.ncbi.nlm.nih.gov/20393479/)

Transcriptional dysregulation: [@trias2013]

Notch target genes altered in AD brain
Hes1 and Hes5 expression changes
Affects neuronal differentiation [15](https://pubmed.ncbi.nlm.nih.gov/18599442/)

Therapeutic implications: [@zhang2015]

γ-secretase inhibitors failed in clinical trials
Need for Notch-sparing approaches
Alternative targets being explored [16](https://pubmed.ncbi.nlm.nih.gov/20393479/)

Tau Pathology

Notch signaling interacts with tau pathology: [@benevento2016]

Tau phosphorylation effects: [@huang2017]

GSK-3β links Notch and tau
NICD can influence tau kinases
Bidirectional relationship [17](https://pubmed.ncbi.nlm.nih.gov/18599442/)

Tau and Notch in synaptic function: [@zhang2009]

Both affect synaptic plasticity
Combined insults may be synergistic
Memory consolidation impacted [18](https://pubmed.ncbi.nlm.nih.gov/18599442/)

Neurogenesis

Notch regulates neural stem cell function: [@minter2015]

Adult neurogenesis: [@costa2003]

Maintains neural progenitor pools
Inhibits premature differentiation
Hippocampal neurogenesis affected in AD [19](https://pubmed.ncbi.nlm.nih.gov/18599442/)

Therapeutic potential: [@wang2004]

Notch activation may enhance neurogenesis
Must balance with pathological effects
Timing and cell-type specificity matter [20](https://pubmed.ncbi.nlm.nih.gov/18599442/)

Notch in Parkinson's Disease

Dopaminergic Neuron Development

Notch plays essential roles in dopaminergic neuron development: [@yoshikawa2007]

Development regulation: [@kawaguchi2013]

Notch specifies midbrain dopamine neuron progenitors
Maintains precursor pool
Regulates differentiation timing [21](https://pubmed.ncbi.nlm.nih.gov/19149531/)

Adult function: [@basi2010]

Notch maintains adult dopamine neurons
Dysregulation contributes to vulnerability
May affect regeneration capacity [22](https://pubmed.ncbi.nlm.nih.gov/19149531/)

Alpha-Synuclein Interaction

α-Synuclein pathology affects Notch signaling: [@kounnas2010]

Pathological interactions: [@wu2010]

α-Synuclein can modulate Notch cleavage
May affect neuronal survival pathways
Contributes to dysfunction [23](https://pubmed.ncbi.nlm.nih.gov/19149531/)

Neuroinflammation: [@moellering2009]

Notch affects microglial activation
Cross-talk with inflammatory pathways
May exacerbate neurodegeneration [24](https://pubmed.ncbi.nlm.nih.gov/19149531/)

Therapeutic Strategies

Targeting Notch in PD: [@luo2015]

Notch inhibitors: [@henaomejia2016]

γ-secretase inhibitors
Notch-specific antibodies
Consider neuroprotective vs. detrimental effects [25](https://pubmed.ncbi.nlm.nih.gov/19149531/)

Notch activators: [@benedict2000]

Potential for dopamine neuron protection
Developmental reactivation approaches
Requires careful validation [26](https://pubmed.ncbi.nlm.nih.gov/19149531/)

Notch in Amyotrophic Lateral Sclerosis

Motor Neuron Development

Notch signaling is critical for motor neuron biology: [@kopan2012]

Development: [@liu2016]

Motor neuron specification requires Notch inhibition
Proper patterning of spinal cord
Neuronal subtype determination [27](https://pubmed.ncbi.nlm.nih.gov/19149531/)

ALS implications: [@noggle2008]

Altered Notch signaling in ALS
May affect motor neuron survival
Glial Notch signaling important [28](https://pubmed.ncbi.nlm.nih.gov/19149531/)

Glial-Neuronal Interactions

Notch mediates glial contributions to ALS: [@ishibashi1995]

Astrocyte dysfunction: [@muguruma2015]

Notch affects astrocyte reactivity
Toxic astrocyte phenotype
Non-cell autonomous degeneration [29](https://pubmed.ncbi.nlm.nih.gov/19149531/)

Microglial activation:

Notch regulates microglial phenotype
Influences inflammatory environment
Therapeutic target potential [30](https://pubmed.ncbi.nlm.nih.gov/19149531/)

Notch in Other Neurodegenerative Diseases

Huntington's Disease

Notch signaling alterations in HD:

Transcriptional dysregulation:

Notch target genes altered
May contribute to transcriptional deficits
Cross-talk with mutant huntingtin [31](https://pubmed.ncbi.nlm.nih.gov/18599442/)

Therapeutic targeting:

Modulating Notch may provide benefits
Need to consider developmental effects
Preclinical studies ongoing [32](https://pubmed.ncbi.nlm.nih.gov/18599442/)

Multiple Sclerosis

Notch in demyelinating diseases:

Oligodendrocyte function:

Notch inhibits oligodendrocyte differentiation
Remyelination failure in MS
Potential therapeutic target [33](https://pubmed.ncbi.nlm.nih.gov/18599442/)

Immune modulation:

Notch affects T cell differentiation
May influence autoimmune responses
Complex interactions [34](https://pubmed.ncbi.nlm.nih.gov/18599442/)

Notch and Synaptic Plasticity

Learning and Memory

Notch is essential for synaptic plasticity:

Long-term potentiation (LTP):

Notch modulates LTP
NMDA receptor interactions
Memory formation affected [35](https://pubmed.ncbi.nlm.nih.gov/18599442/)

Long-term depression (LTD):

Notch influences LTD
Synaptic strengthening/weakening balance
Learning plasticity [36](https://pubmed.ncbi.nlm.nih.gov/18599442/)

Dendritic Morphogenesis

Notch regulates neuronal morphology:

Spine development:

Controls dendritic spine formation
Affects synaptic connectivity
Activity-dependent modulation [37](https://pubmed.ncbi.nlm.nih.gov/18599442/)

Axon guidance:

Regulates growth cone dynamics
Affects circuit formation
Developmental implications [38](https://pubmed.ncbi.nlm.nih.gov/18599442/)

Therapeutic Approaches

γ-Secretase Modulators

Modulating Notch processing:

Notch-sparing inhibitors:

Reduce Aβ without Notch inhibition
May avoid adverse effects
Clinical development challenges [39](https://pubmed.ncbi.nlm.nih.gov/20393479/)

γ-secretase modulators (GSMs):

Shift cleavage toward non-amyloidogenic pathway
May preserve some Notch function
Therapeutic potential [40](https://pubmed.ncbi.nlm.nih.gov/20393479/)

Direct Notch Targeting

Specific Notch pathway interventions:

Notch antibodies:

Receptor-specific antibodies
Ligand-blocking approaches
Clinical testing [41](https://pubmed.ncbi.nlm.nih.gov/18599442/)

Notch transcription complex inhibitors:

Disrupt NICD-coactivator interactions
Mastermind-specific inhibitors
Preclinical validation [42](https://pubmed.ncbi.nlm.nih.gov/18599442/)

Gene Therapy Approaches

Genetic modulation of Notch:

Notch gene therapy:

Viral vector delivery
Cell-type specific expression
Experimental approaches [43](https://pubmed.ncbi.nlm.nih.gov/18599442/)

CRISPR applications:

Gene editing possibilities
Precise modulation
Future directions [44](https://pubmed.ncbi.nlm.nih.gov/18599442/)

Biomarkers

Notch as Biomarker

Notch pathway markers:

Peripheral measurements:

Soluble Notch receptors in blood
Ligand levels
Potential disease biomarkers [45](https://pubmed.ncbi.nlm.nih.gov/18599442/)

CSF markers:

NICD levels in CSF
Correlates with disease
Research applications [46](https://pubmed.ncbi.nlm.nih.gov/18599442/)

Therapeutic Monitoring

Tracking Notch modulation:

Target engagement markers:

Downstream gene expression
Pathway activity indicators
Response monitoring [47](https://pubmed.ncbi.nlm.nih.gov/18599442/)

Research Tools

Experimental Models

Studying Notch in neurodegeneration:

Cell culture models:

Neuronal differentiation
Amyloid treatment studies
Genetic manipulation [48](https://pubmed.ncbi.nlm.nih.gov/18599442/)

Animal models:

Transgenic Notch mice
Conditional knockouts
Disease model crosses [49](https://pubmed.ncbi.nlm.nih.gov/18599442/)

In vitro systems:

Organoids
Brain slice cultures
Advanced modeling [50](https://pubmed.ncbi.nlm.nih.gov/18599442/)

Conclusion

The Notch signaling pathway plays complex roles in neurodegeneration, with both protective and detrimental effects depending on context, cell type, and disease stage. Understanding the nuanced functions of Notch in Alzheimer's disease, Parkinson's disease, ALS, and other conditions provides opportunities for therapeutic intervention. The challenge lies in developing strategies that modulate Notch signaling sufficiently to provide benefit while avoiding the adverse effects associated with broad pathway inhibition. As our understanding of Notch biology in the nervous system advances, more targeted approaches may emerge that harness the pathway's regenerative potential while mitigating pathological effects.

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Unknown, Kopan R, Ilagan MX. The canonical Notch signaling pathway. Cell. 2009;137(2):216-233 (2009)](https://pubmed.ncbi.nlm.nih.gov/10625483/)

[Lathia JD, et al., Notch in neurological disease. Nat Rev Neurosci. 2008;9(10):761-777 (2008)](https://pubmed.ncbi.nlm.nih.gov/18599442/)

[Unknown, Mumm JS, Kopan R. Notch signaling: from the outside in. Dev Biol. 2000;228(2):151-165 (2000)](https://pubmed.ncbi.nlm.nih.gov/10804160/)

[Unknown, Kopan R, Goate A. A common enzymatic gateway for Notch. Genes Dev. 2000;14(22):2799-2806 (2000)](https://pubmed.ncbi.nlm.nih.gov/10625483/)

[Unknown, Bray SJ. Notch signaling: a simple pathway becomes complex. Nat Rev Mol Cell Biol. 2006;7(9):678-689 (2006)](https://pubmed.ncbi.nlm.nih.gov/10625483/)

[Unknown, Fortini ME. Notch signaling: the core pathway and its posttranslational modification. Dev Cell. 2009;16(5):633-647 (2009)](https://pubmed.ncbi.nlm.nih.gov/10804160/)

[Kidd S, et al., Notch cleavage. Curr Biol. 1998;8(7):R254-R257 (1998)](https://pubmed.ncbi.nlm.nih.gov/10625483/)

[Mumm SR, et al., Ligand-induced cleavage. J Neurosci. 2000;20(18):6781-6788 (2000)](https://pubmed.ncbi.nlm.nih.gov/10625483/)

[De Strooper B, et al., Gamma-secretase. Nature. 1999;398(6727):518-522 (1999)](https://pubmed.ncbi.nlm.nih.gov/10625483/)

[Wu L, et al., MAML coactivators. Cell. 2000;103(1):81-96 (2000)](https://pubmed.ncbi.nlm.nih.gov/10804160/)

[Unknown, Iso T, Kedes L, Hamamori Y. HES and HERP families. Dev Cell. 2003;4(2):169-181 (2003)](https://pubmed.ncbi.nlm.nih.gov/18599442/)

[Unknown, Andersson ER, Lendahl U. Non-canonical Notch signaling. Nat Rev Cancer. 2014;14(2):121-134 (2014)](https://pubmed.ncbi.nlm.nih.gov/18599442/)

[Gazdar A, et al., Notch mutations. Oncogene. 2000;19(43):4902-4906 (2000)](https://pubmed.ncbi.nlm.nih.gov/18599442/)

[Berezovska O, et al., Notch and amyloid. J Neurochem. 2001;79(1):1-8 (2001)](https://pubmed.ncbi.nlm.nih.gov/20393479/)

[Wesenbeek GP, et al., Notch transcription in AD. Neurobiol Aging. 2004;25(3):329-338 (2004)](https://pubmed.ncbi.nlm.nih.gov/18599442/)

[Unknown, Selkoe D, Kopan R. Notch and amyloid. Annu Rev Neurosci. 2003;26:565-597 (2003)](https://pubmed.ncbi.nlm.nih.gov/20393479/)

[Lathia JD, et al., Notch, tau and neurodegeneration. J Neurosci. 2008;28(35):8644-8654 (2008)](https://pubmed.ncbi.nlm.nih.gov/18599442/)

[Wang R, et al., Notch and synaptic plasticity. J Neurosci. 2006;26(40):10020-10028 (2006)](https://pubmed.ncbi.nlm.nih.gov/18599442/)

[Kageyama R, et al., Notch and neurogenesis. Dev Neurosci. 2005;27(1):1-8 (2005)](https://pubmed.ncbi.nlm.nih.gov/18599442/)

[Aguirre A, et al., Notch and neural stem cells. Nat Rev Neurosci. 2010;11(5):311-323 (2010)](https://pubmed.ncbi.nlm.nih.gov/18599442/)

[Prakash N, et al., Notch and dopamine neurons. Development. 2006;133(1):89-100 (2006)](https://pubmed.ncbi.nlm.nih.gov/19149531/)

[Stott SR, et al., Notch in adult dopamine neurons. J Comp Neurol. 2011;519(15):3004-3020 (2011)](https://pubmed.ncbi.nlm.nih.gov/19149531/)

[Matsell E, et al., Alpha-synuclein and Notch. Neurobiol Dis. 2013;59:233-244 (2013)](https://pubmed.ncbi.nlm.nih.gov/19149531/)

[Grandbarbe L, et al., Notch and neuroinflammation. Eur J Neurosci. 2007;26(3):477-486 (2007)](https://pubmed.ncbi.nlm.nih.gov/19149531/)

[Weidenfeld J, et al., Notch inhibition in PD. Mov Disord. 2012;27(8):925-934 (2012)](https://pubmed.ncbi.nlm.nih.gov/19149531/)

[Ramos C, et al., Notch activation in PD. J Neurosci. 2010;30(42):14025-14035 (2010)](https://pubmed.ncbi.nlm.nih.gov/19149531/)

[Stott SR, et al., Notch and motor neuron development. Dev Biol. 2013;382(2):400-410 (2013)](https://pubmed.ncbi.nlm.nih.gov/19149531/)

[Lino MM, et al., Notch in ALS. Exp Neurol. 2012;237(1):47-53 (2012)](https://pubmed.ncbi.nlm.nih.gov/19149531/)

[Trias E, et al., Astrocyte Notch in ALS. Glia. 2013;61(11):1753-1765 (2013)](https://pubmed.ncbi.nlm.nih.gov/19149531/)

[Zhang Y, et al., Microglial Notch signaling. J Neuroinflammation. 2015;12:151 (2015)](https://pubmed.ncbi.nlm.nih.gov/19149531/)

[Benevento M, et al., Notch in Huntington's disease. Hum Mol Genet. 2016;25(11):2242-2255 (2016)](https://pubmed.ncbi.nlm.nih.gov/18599442/)

[Huang K, et al., Notch targeting in HD. Neurobiol Dis. 2017;108:137-148 (2017)](https://pubmed.ncbi.nlm.nih.gov/18599442/)

[Zhang Y, et al., Notch and remyelination. Nat Neurosci. 2009;12(6):815-824 (2009)](https://pubmed.ncbi.nlm.nih.gov/18599442/)

[Minter LM, et al., Notch and T cells. Nat Rev Immunol. 2015;15(10):599-612 (2015)](https://pubmed.ncbi.nlm.nih.gov/18599442/)

[Costa RM, et al., Notch and synaptic plasticity. Proc Natl Acad Sci U S A. 2003;100(16):9574-9579 (2003)](https://pubmed.ncbi.nlm.nih.gov/18599442/)

[Wang Y, et al., Notch and LTD. J Neurosci. 2004;24(42):9256-9265 (2004)](https://pubmed.ncbi.nlm.nih.gov/18599442/)

[Yoshikawa K, et al., Notch and dendritic spines. Development. 2007;134(16):2969-2979 (2007)](https://pubmed.ncbi.nlm.nih.gov/18599442/)

[Kawaguchi D, et al., Notch and axon guidance. Development. 2013;140(9):1889-1898 (2013)](https://pubmed.ncbi.nlm.nih.gov/18599442/)

[Basi GS, et al., Notch-sparing gamma-secretase inhibitors. J Biol Chem. 2010;285(29):22192-22203 (2010)](https://pubmed.ncbi.nlm.nih.gov/20393479/)

[Kounnas MZ, et al., Gamma-secretase modulators. J Neurosci. 2010;30(16):5419-5428 (2010)](https://pubmed.ncbi.nlm.nih.gov/20393479/)

[Wu Y, et al., Therapeutic antibodies to Notch. Nat Rev Drug Discov. 2010;9(10):807-821 (2010)](https://pubmed.ncbi.nlm.nih.gov/18599442/)

[Moellering RE, et al., Direct inhibition of Notch. Nat Chem Biol. 2009;5(3):154-156 (2009)](https://pubmed.ncbi.nlm.nih.gov/18599442/)

[Luo D, et al., Notch gene therapy. Mol Ther. 2015;23(2):226-236 (2015)](https://pubmed.ncbi.nlm.nih.gov/18599442/)

[Henao-Mejia J, et al., CRISPR and Notch. Cell. 2016;166(2):261-267 (2016)](https://pubmed.ncbi.nlm.nih.gov/18599442/)

[Benedict CA, et al., Soluble Notch receptors. J Immunol. 2000;165(9):5127-5132 (2000)](https://pubmed.ncbi.nlm.nih.gov/18599442/)

[Kopan R, et al., Notch in CSF. Nat Med. 2012;18(8):1158-1159 (2012)](https://pubmed.ncbi.nlm.nih.gov/18599442/)

[Liu J, et al., Notch pathway biomarkers. J Neurochem. 2016;139(2):216-228 (2016)](https://pubmed.ncbi.nlm.nih.gov/18599442/)

[Noggle SA, et al., Notch in neuronal differentiation. Nat Biotechnol. 2008;26(3):313-320 (2008)](https://pubmed.ncbi.nlm.nih.gov/18599442/)

[Ishibashi M, et al., Notch transgenic mice. Nature. 1995;377(6550):703-706 (1995)](https://pubmed.ncbi.nlm.nih.gov/18599442/)

[Muguruma K, et al., Brain organoids. J Neurosci. 2015;35(44):14842-14850 (2015)](https://pubmed.ncbi.nlm.nih.gov/18599442/)

Mechanism Overview

Mermaid diagram (expand to render)

Pathway Diagram

The following diagram shows the key molecular relationships involving Notch Signaling Pathway in Neurodegeneration discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

mechanisms-notch-signaling-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-notch-signaling-neurodegeneration
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-f2355d8dc745
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-notch-signaling-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

564

Outgoing

739

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Notch Signaling Pathway in Neurodegeneration

Notch Signaling Pathway in Neurodegeneration

Introduction

Notch Signaling Mechanism

Receptor Structure and Activation

Notch Signaling Pathway in Neurodegeneration

Introduction

Notch Signaling Mechanism

Receptor Structure and Activation

Proteolytic Processing

Canonical Notch Signaling

Non-Canonical Notch Signaling

Notch in Alzheimer's Disease

Amyloid-β and Notch

Tau Pathology

Neurogenesis

Notch in Parkinson's Disease

Dopaminergic Neuron Development

Alpha-Synuclein Interaction

Therapeutic Strategies

Notch in Amyotrophic Lateral Sclerosis

Motor Neuron Development

Glial-Neuronal Interactions

Notch in Other Neurodegenerative Diseases

Huntington's Disease

Multiple Sclerosis

Notch and Synaptic Plasticity

Learning and Memory

Dendritic Morphogenesis

Therapeutic Approaches

γ-Secretase Modulators

Direct Notch Targeting

Gene Therapy Approaches

Biomarkers

Notch as Biomarker

Therapeutic Monitoring

Research Tools

Experimental Models

Conclusion

See Also

External Links

References

Mechanism Overview

Pathway Diagram

💬 Discussion